Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $2.83 Average Target Price from Analysts

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $2.8333.

CGTX has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Cognition Therapeutics in a research note on Wednesday, October 8th. Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of Cognition Therapeutics in a research note on Friday, August 8th. Finally, Wall Street Zen lowered shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 26th.

Cognition Therapeutics Price Performance

Shares of NASDAQ:CGTX opened at $1.65 on Tuesday. The company’s fifty day moving average price is $1.91 and its 200 day moving average price is $1.02. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The firm has a market capitalization of $121.31 million, a P/E ratio of -2.46 and a beta of 1.19.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. On average, sell-side analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. CM Management LLC boosted its holdings in shares of Cognition Therapeutics by 100.0% in the first quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $168,000 after acquiring an additional 200,000 shares in the last quarter. Northeast Financial Consultants Inc boosted its holdings in shares of Cognition Therapeutics by 158.6% in the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock valued at $27,000 after acquiring an additional 38,851 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Cognition Therapeutics by 814.1% in the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock valued at $422,000 after acquiring an additional 897,353 shares in the last quarter. DAVENPORT & Co LLC purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at about $3,631,000. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at about $34,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.